metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
mHNSCC - L2 - all population metastatic-recurrent HNSCC (mHNSCC) mHNSCC - 2nd line (L2) mHNSCC - L2 - all population
versus Standard of Care (SoC)
	durvalumab plus tremelimumab
	EAGLE (DT vs ICC), 2019 Journal of Clinical Oncology Ann Oncol 2020 Jul;31(7):942-950. NCT02369874	RCT	mHNSCC - L2 - all population	durvalumab plus tremelimumab	investigator’s choice: cetuximab, taxane, methotrexate, or fluoropyrimidine-based regimen	patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).of the oral cavity, oropharynx, hypopharynx, or larynx not amenable to curative therapy who had progression or recurrence during or after only one systemic treatment regimen containing a platinum agent	247 / 249	some concern	inconclusive	inconclusive 4 % increase in deaths (OS) (PE)
mHNSCC - L2 - PDL1 negative metastatic-recurrent HNSCC (mHNSCC) mHNSCC - 2nd line (L2) mHNSCC - L2 - PDL1 negative
versus durvalumab alone
	durvalumab plus tremelimumab
	CONDOR (DT vs D ; PDL1 TC<25%), 2019 JAMA Oncol 2019; 5:195-203 NCT02319044	RCT	mHNSCC - L2 - PDL1 negative	durvalumab plus tremelimumab	durvalumab monotherapy	patients with recurrent or metastatic HNSCC (PD-L1-low/negative) that had progressed after 1 platinum-containing regimen in the R/M setting	133 / 67	high	inconclusive	inconclusive 17 % decrease in objective responses (ORR) (PE) statistically significant 8.4-fold increase in STRAE (any grade)
versus tremelimumab
	durvalumab plus tremelimumab
	CONDOR (DT vs T ; PDL1 TC<25%), 2019 JAMA Oncol 2019; 5:195-203 NCT02319044	RCT	mHNSCC - L2 - PDL1 negative	durvalumab plus tremelimumab	tremelimumab monotherapy	patients with recurrent or metastatic HNSCC (PD-L1-low/negative) that had progressed after 1 platinum-containing regimen in the R/M setting	133 / 67	high	suggested	inconclusive 4.2-fold increase in objective responses (ORR) (PE)